Previous Article | Next Article 
Infect Immun, April 1998, p. 1421-1426, Vol. 66, No. 4
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The Protective Effects of Lactoferrin Feeding
against Endotoxin Lethal Shock in Germfree Piglets
Wang J.
Lee,1,
Jeffrey L.
Farmer,2
Milo
Hilty,3 and
Yoon B.
Kim1,*
Finch University of Health Sciences/The
Chicago Medical School, North Chicago,1 and
Abbott Laboratories, Abbott Park,2
Illinois 60064, and
Ross Laboratories, Columbus, Ohio
432153
Received 10 November 1997/Returned for modification 22 December
1997/Accepted 15 January 1998
 |
ABSTRACT |
The unique germfree, colostrum-deprived, immunologically
"virgin" piglet model was used to evaluate the ability of
lactoferrin (LF) to protect against lethal shock induced by
intravenously administered endotoxin. Piglets were fed LF or bovine
serum albumin (BSA) prior to challenge with intravenous
Escherichia coli lipopolysaccharide (LPS), and
temperature, clinical symptoms, and mortality were tracked for 48 h following LPS administration. Prefeeding with LF resulted in a
significant decrease in piglet mortality compared to feeding with BSA
(16.7 versus 73.7% mortality, P < 0.001). Protection
against the LPS challenge by LF was also correlated with both
resistance to induction of hypothermia by endotoxin and an overall
increase in wellness, as quantified by a toxicity score developed for
these studies. In vitro studies using a flow cytometric assay system
demonstrated that LPS binding to porcine monocytes was inhibited by LF
in a dose-dependent fashion, suggesting that the mechanism of LF action
in vivo may be inhibition of LPS binding to monocytes/macrophages and,
in turn, prevention of induction of monocyte/macrophage-derived
inflammatory-toxic cytokines.
 |
INTRODUCTION |
Despite the development of potent,
broad-spectrum antibiotics, septic shock remains both the most frequent
cause of death of intensive care patients and the 13th leading cause of
death overall in the United States (20). Death from septic
shock is thought to be a consequence of the effect of monocyte-derived cytokines such as tumor necrosis factor alpha (TNF-
), interleukin 1 (IL-1), and IL-6, which are induced in response to bacterial endotoxin
(lipopolysaccharide [LPS]). A number of approaches that block the
action of endotoxin on target cells have been evaluated as potential
therapies for septic shock, including anti-LPS monoclonal antibodies
(MAbs) and anti-TNF-
antibody (4, 31). The results of
these evaluations have been mixed at best. Recently, a number of
reports have suggested that the naturally occurring protein lactoferrin
(LF) may be a therapeutic candidate for septic shock (1,
14).
LF is a 77-kDa iron binding glycoprotein found in high levels in
various secretions, e.g., milk and pancreatic juice (25), and is resistant to acids and several proteases (19).
Because LF is very stable, it can be used in in vivo experiments to
investigate its protective effects against lethal shock due to
endotoxin. In vitro studies have demonstrated both bacteriostatic
(6, 18, 28) and bactericidal (2, 3, 8, 9)
activities of LF for gram-negative organisms via two possible
mechanisms. One is to chelate iron ions, which are essential for
bacterial growth (5, 6), and the other is to destabilize the
outer membrane of gram-negative organisms (8). Recently, it
was reported that LF exhibits binding activity for the lipid A portion
of LPS, which may serve to inhibit monocyte activation and cytokine
production by interfering with the access of endotoxin to its cell
surface receptor (1).
In the current study, we have tested the ability of oral LF to modulate
lethal endotoxin shock in vivo. As a model system, we have employed the
unique, germfree (GF), colostrum-deprived, immunologically "virgin"
Minnesota miniature piglet (13) and oral feeding of LF that
will allow introduction of intact LF into the blood circulation via
gastrointestinal absorption (16). The use of this unique
model system allows the study of the response to true primary toxicity
of endotoxin (the lipid A portion of LPS) in the absence of any
secondary toxicity due to the acquisition of hypersensitivity by the
host to some portion of the LPS preparation, namely, O and R
polysaccharides and contaminating peptides. The primary and secondary
toxicities are interdependent, depending on the immunological state of
the host. Therefore, the biological activity of the endotoxin will vary
not only because of the heterogenicity of the preparation but also
because of its dependency on the immunological reactions of the host to
the various portions of the endotoxin (10-12, 27). (i) In
immunologically virgin animals, which have neither hypersensitivity nor
acquired immunity, biological activity is due entirely to the primary
toxicity of the lipid A portion of the endotoxin. (ii) So-called normal
animals may have been exposed to the environment (microbes, endotoxins)
and will develop hypersensitivity, as well as acquired immunity, to
various degrees and will have various degrees of susceptibility. Here,
both the primary and secondary toxicities interdependently enhance
their activities, and interaction due to various low degrees of
acquired immunity (the anti-lipid A portion of endotoxin) is also
possible. (iii) Sensitized animals have a high degree of
hypersensitivity and a low degree of immunity. Here, primary toxicity
and secondary toxicity will be greatly enhanced interdependently, and
the animals become extremely susceptible to the endotoxin. (iv) In
immunized animals (so-called tolerant animals), in which the degree of
hypersensitivity is not important because the primary toxicity is
blocked by antiendotoxin antibody, secondary toxicity is not enhanced
and acts to desensitize the animals. We demonstrated that so-called
tolerance is, in fact, specific immunity to the endotoxin (the lipid A
portion) due to 19S antibodies which are capable of assisting
phagocytes to detoxify the primary toxicity. Antibodies to O and R
polysaccharides play a little role in antiendotoxin immunity and may
actually contribute to secondary toxicity. Thus, we will be able to
examine the protective effects of LF against the primary toxicity of
endotoxin (LPS)-induced lethal shock.
 |
MATERIALS AND METHODS |
Animals.
GF, colostrum-deprived, immunologically virgin,
neonatal Minnesota miniature piglets were aseptically obtained by
hysterectomy 0 to 5 days prior to term (the expected date of
confinement [EDC]). The body weights of newborn GF piglets ranged
from 450 to 650 g. Randomly selected littermates were maintained
in GF isolators and fed a milk-free soy protein formula, Nursoy (Wyeth
Laboratories, Inc., Philadelphia, Pa.). Young adult,
specific-pathogen-free Minnesota miniature swine were maintained in a
barrier-sustained facility with filtered air (HEPA filter) and fed with
an autoclaved diet and chlorinated water.
All GF piglet littermates were divided into three groups. Group A, the
LF-LPS group, was fed with 2,000 mg of sterile LF (Tatua Biologics,
Morrinsville, New Zealand) in 10 ml of phosphate-buffered saline (PBS)
by gastric tube at 0, 8, and 20 h after birth and fed with 20 mg
of sterile LF per ml of Nursoy (diluted 1:2 with distilled water) every
4 h after birth. Group B, the bovine serum albumin (BSA)-LPS
group, was fed with 2,000 mg of sterile BSA (A2153, fraction V, 96%
pure; Sigma Chemical Co., St. Louis, Mo.) in 10 ml of PBS by gastric
tube at 0, 8, and 20 h after birth and fed with 20 mg of sterile
BSA per ml of Nursoy (diluted 1:2 with distilled water) every 4 h
after birth. Group C, the control group, was fed with only 10 ml of
sterile PBS (pH 7.2) by gastric tube at 0, 8, and 20 h after birth
and maintained with sterile Nursoy (diluted 1:2 with distilled water)
given every 4 h after birth. Both groups A and B were injected
with 750 or 850 µg of Escherichia coli O55:B5 LPS (L-2637,
lot 123H4024; Sigma Chemical Co.) per kg of body weight into the
jugular vein at 23 h after birth (3 h after the last tube feeding
of LF or BSA), while group C was injected with only 1 ml of PBS. Rectal
temperatures were measured, and clinical symptoms (degree of weakness,
degree of food intake, and death) were observed at 0, 1, 2, 3, 6, 9, 12, 20, 24, 28, 32, 36, 44, and 48 h after LPS injection.
Bovine LF.
Bovine LF was purchased from Tatua Biologics
(batch TB194048) and was >95% pure, as judged by polyacrylamide gel
electrophoresis. Fluorescein isothiocyanate (FITC)-labelled E. coli O55:B5 LPS (catalog no. F7632) was purchased from Sigma
Chemical Co. Anti-CD14 MAb My23.5 was kindly supplied by Michael
Fanger, Dartmouth Medical School, and goat anti-mouse immunoglobulin
G-FITC was purchased from Southern Biotech (Birmingham, Ala.). RPMI
1640 with HEPES was the product of BioWhittaker, Walkersville, Md.
PBM isolation.
Porcine peripheral blood mononuclear cells
(PBMs) were isolated from whole blood of young adult,
specific-pathogen-free swine by density gradient centrifugation on
Histopaque (Sigma Chemical Co.). Whole blood was diluted 1:3 with
Dulbecco's PBS (Ca2+ and Mg2+ free) and
layered on 10 ml of Histopaque in a 50-ml conical tube (maximum of 25 ml of diluted blood/tube). Gradients were centrifuged at 400 × g and room temperature for 35 min, and the PBM layer was
harvested by aspiration with a Pasteur pipette. The pooled PBMs were
washed twice with 12 ml of cold RPMI 1640 and resuspended in 10 to 12 ml of cold RPMI 1640. Cell yield was determined by hemocytometer
counting, using trypan blue to determine the viability of the cells.
Flow cytometric analysis of LPS binding to PBMs.
A flow
cytometric assay was developed to assess the effect of LF on the
binding of LPS to porcine PBMs. PBMs isolated as described above were
resuspended at 5 × 106/ml in cold RPMI 1640 supplemented with 10% (vol/vol) heat-inactivated (56°C, 30 min)
autologous serum. A 200-µl volume of the cell suspension was mixed
with 100 µl of LF in RPMI 1640 at the indicated concentration or with
RPMI 1640 alone and then preincubated on ice for 15 min. Following this
incubation, 10 µl of 200-µg/ml LPS-FITC (E. coli O55:B5;
Sigma) was added (6.45-µg/ml final concentration) and the mixture was
incubated for an additional 60 min at 4°C. The incubation was
terminated by addition of 1 ml of cold assay buffer (PBS-2% fetal
bovine serum-0.1% azide), followed by centrifugation. The cell
supernatant was discarded, and the cells were washed twice with 1 ml of
cold assay buffer and then resuspended in 500 µl of cold assay
buffer. Cells were kept on ice until flow cytometer analysis. In
studies on the role of monocyte CD14 antigen in LPS binding in this
model system, anti-CD14 MAb My23.5 was substituted for the LF in the
above-described protocol at a final concentration of 2 µg/ml, and the
cells were preincubated with the MAb for 30 min on ice prior to the
addition of LPS-FITC.
Flow cytometric analysis of LPS-FITC binding was done on a Becton
Dickinson FACScan by using logarithmic amplification of the FITC
fluorescence signal, and the data were acquired on a total of 10,000 PBMs/sample. For routine analysis of LPS-FITC binding to monocytes, dot
plots of forward light scatter versus 90° light scatter were used to
differentiate lymphocytes and monocytes, based on the elevated 90°
light scatter of the latter. Flow cytometric analysis of cells stained
with the anti-CD14 MAb, followed by anti-mouse immunoglobulin G-FITC,
demonstrated that, typically, >80% of the cells falling within the
monocyte light scatter gate reacted with this monocyte-specific MAb
(data not shown). For analysis, a cutoff was set on the negative
control population, such that less than 1% of the total monocytes were
scored as positive for LPS-FITC binding, and the percentage of cells
binding LPS-FITC was determined for the experimental samples. The
percent inhibition of LPS-FITC binding to monocytes was calculated by
using the following formula: % inhibition of LPS-FITC binding = [1
(% positive monocytes with inhibitor
% positive
monocytes in negative control)/(% positive monocytes without
inhibitor
% positive monocytes in negative control)] × 100.
 |
RESULTS |
Effect of LF on lethal endotoxin shock.
All GF piglets were
divided into three groups. Those in group A (LF-LPS) were fed with LF
to observe the protective effect against a lethal endotoxin shock. For
comparison, those in group B (BSA-LPS) were fed with BSA, which is
known to have no effect on endotoxin lethality (data not shown). Those
in group C (control) were fed with PBS alone as an additional
control. All GF piglets were fed by gastric tube to administer measured
amounts of LF, BSA, and PBS. Each group was randomly assigned
from each sex after division of littermates into males and females. The
dosages (LD75) of LPS injected intravenously (i.v.) were
750 µg/kg for GF piglets obtained 3 to 5 days prior to EDC and those
with less than 500 g of body weight obtained 0 to 2 days prior to
EDC and 850 µg/kg for GF piglets with over 500 g of body weight
obtained 0 to 2 days prior to EDC.
The results in Table 1 demonstrate that
there was a marked difference (16.7 versus 73.7%) in the mortality
induced by endotoxin between the LF-LPS and BSA-LPS groups
(P < 0.001). In both the LF-LPS and BSA-LPS groups,
more than 30% of the deaths (1 of 3 in the LF-LPS group, 5 of 14 in
the BSA-LPS group) took place within 12 h, more than 60% of the
deaths (2 of 3 in the LF-LPS group, 9 of 14 in the BSA-LPS group) took
place within 24 h, and more than 90% of the deaths (3 of 3 in the
LF-LPS group, 13 of 14 in the BSA-LPS group) took place within 36 h.
Changes in rectal temperature and toxicity score.
Rectal
temperatures were measured by an electronic digital thermometer. For
objective evaluation of the clinical symptoms, a toxicity scoring
system was developed (Table 2). In this
scoring system, a high score indicates strong endotoxin toxicity.
The GF7042 littermates consisted of only two piglets, one treated with
LF-LPS and the other treated with BSA-LPS. The LF-LPS piglet showed
initial hypothermia followed by recovery, and the BSA-LPS piglet showed
no such recovery and died after 24 h (Fig. 1A). The BSA-LPS piglet showed increasing
toxicity until the piglets died 24 h after injection, but the
LF-LPS piglet maintained a lower toxicity score (Fig. 1a).

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of LF on the rectal temperatures (A, B, C, D) and
toxicity scores (a, b, c, d) of GF piglets injected i.v. with LPS. LF
or BSA (2,000 mg) was fed by gastric tube every 8 h for 1 day,
followed by i.v. injection of LPS at 750 µg/kg, and GF piglets were
maintained on 20 mg of LF or BSA per ml of Nursoy diet, and then rectal
temperatures and toxicity scores were measured at 0, 1, 2, 3, 6, 9, 12, 20, 24, 28, 32, 36, 44, and 48 h after injection. , death.
|
|
The GF7046 littermates consisted of four piglets. Two were treated with
LF-LPS, and the other two were treated with BSA-LPS. The LF-LPS group
was able to maintain normal body temperatures, while the BSA-LPS
group immediately became hypothermic and one piglet died within 24 h after injection (Fig. 1B). The LF-LPS group showed consistently
low toxicity scores, while the BSA-LPS group had increased toxicity
scores (Fig. 1b).
The GF7047 littermates, consisting of six piglets, showed patterns of
change in rectal temperature and toxicity score very similar to those
of GF7046 littermates. In this set of littermates, one animal was
included as a control and given 10 ml of sterile PBS by gastric tube
and no LPS challenge. There were no differences in rectal temperature
and toxicity score between the control group and the LF-LPS group (Fig.
1C and c).
Four GF7057 littermates presented very simple and clear results. Both
piglets in the BSA-LPS group showed severe hypothermia with body
temperatures dropping to 90°F, resulting in death between 9 and
12 h after LPS administration, whereas both piglets in the LF-LPS
group showed mild hyperthermia rather than hypothermia within 12 h
after LPS injection. The latter piglets appeared to be unaffected by
the injected endotoxin and showed very low toxicity scores, while the
former piglets died (toxicity score higher than 12) a short time after
LPS injection (Fig. 1D and d).
Two GF7049 and two GF7050 littermates from two hysterectomies
performed at the same time were randomly divided into three groups
(three in the LF-LPS group, three in the BSA-LPS group, and two in the
control group). The two former groups were injected with 850 µg of
LPS per kg of body weight according to the criteria of dosage
determination (body weights were greater than 500 g). The
temperatures of all of the piglets in the BSA-LPS group and 2 in
the LF-LPS group acutely dropped to or below 94°F. All of these
piglets subsequently died. The remaining piglet in the LF-LPS group was
healthy and strong and showed no hypothermia, despite LPS injection.
The changing toxicity score pattern of these littermates was similar to
the body temperature pattern (Fig. 2A and
a).

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of LF on rectal temperatures (A, B, C, D) and
toxicity scores (a, b, c, d) of GF piglets injected i.v. with LPS. LF
or BSA (2,000 mg) was fed by gastric tube every 8 h for 1 day,
followed by i.v. injection of 750 or 850 µg of LPS per kg, and GF
piglets were maintained on 20 mg of LF or BSA per ml of Nursoy diet,
and then rectal temperatures and toxicity scores were measured at 0, 1, 2, 3, 6, 9, 12, 20, 24, 28, 32, 36, 44, and 48 h after injection.
, death.
|
|
The GF7051 littermates were composed of five piglets (two in the LF-LPS
group, two in the BSA-LPS group, and one in the control group). All
piglets in the BSA-LPS group, except one, which showed severe
hypothermia and died within 36 h after injection, showed mild
hypothermia down to 96°F and kept their temperatures at that level
(Fig. 2B and b).
Six GF7052 littermates were divided randomly into three groups of two
piglets. While all of the piglets in the LF-LPS group and one in the
control group had relatively constant body temperatures, all in the
BSA-LPS group (two piglets) showed a rapid drop in body temperature for
the initial 3 h after LPS injection and thereafter showed
temperature fluctuations for more than 20 h, eventually dying.
Although all in the BSA-LPS group showed relatively low toxicity scores
(less than 10), they all died around 24 h after injection (Fig. 2C
and c).
The GF7062 littermates were six piglets (two in the LF-LPS group,
two in the BSA-LPS group, and two in the control group). All piglets in
the LF-LPS and BSA-LPS groups showed an initial acute drop in
body temperature, while all in the control group were in the normal
range. One in the LF-LPS group recovered from hypothermia, while
another died around 12 h after injection. Two in the BSA-LPS group
also recovered from hypothermia to a lesser extent than one piglet of
the LF-LPS group, but they were unable to drink Nursoy by themselves
and had a gradual increase in toxicity score to 10. Eventually, both of
them died at 23 and 33 h after LPS injection (Fig. 2D and d).
Characterization of LPS-FITC binding to porcine monocytes.
A
flow cytometric assay was developed to monitor LPS binding to porcine
PBMs. Density gradient-isolated cells were incubated with FITC-labelled
E. coli LPS in the presence of autologous serum, and binding
to PBMs was characterized by flow cytometry. Only LPS-FITC binding to
monocytes was observed, as assessed by light scatter, and no
significant binding to cells with light scatter characteristic of
lymphocytes was noted (data not shown). Dose-response curves of
LPS-FITC concentration versus percent positive cells demonstrated that
40 to 60% of the cells with light scatter characteristics of monocytes
were positive for LPS-FITC binding (Fig.
3). To verify that the cells binding
LPS-FITC were, in fact, monocytes, cells were preincubated with a MAb
to porcine CD14, a monocyte-specific antigen which has been shown to
function as a receptor for LPS in humans (29). As the
results in Fig. 3 demonstrate, the anti-porcine CD14 MAb was effective
in blocking LPS-FITC binding to PBMs, suggesting that all LPS binding
occurs on monocytes.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of anti-CD14 MAb on LPS binding to porcine
monocytes. Percent binding of LPS to porcine monocytes without the
anti-CD14 MAb (open symbols) and with the anti-CD14 MAb (2 µg)
(closed symbols) is shown. SPF, specific pathogen free.
|
|
Effect of LF on LPS binding to porcine monocytes.
The
flow cytometric assay was used to examine the effect of the
preincubation of monocytes with LF on LPS-FITC binding. Isolated PBMs were incubated at 4°C for 15 min with various concentrations of
LF, and then a fixed concentration of LPS-FITC was added. Cells were
analyzed by flow cytometry, and the percent inhibition of LPS-FITC
binding to monocytes was determined as described in Materials and
Methods. As the results in Fig. 4
demonstrate, preincubation of cells with LF resulted in dose-dependent
inhibition of LPS-FITC binding to porcine monocytes. Fifty percent
inhibition of LPS binding under these conditions required an
approximately 1:1 weight ratio of LF to LPS.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Percent inhibition of LPS binding to porcine
monocytes by LF. Porcine PBMs (5 × 106/ml) were
incubated with various concentrations of LF, and then LPS-FITC binding
was analyzed by flow cytometer, and percent inhibition was calculated
as described in Materials and Methods. SPF, specific pathogen free.
|
|
 |
DISCUSSION |
In the present study, the effect of oral LF administration on the
response to lethal shock induced by intravenous LPS administration was
studied in a GF, colostrum-deprived, immunologically virgin piglet
model. Prefeeding of LF was clearly associated with a significant decrease in mortality, specifically, 17% for LF versus 74% for control animals fed BSA (Table 1; P < 0.001). These
results represent the first report that oral administration of LF can
significantly modify septic shock. In an earlier study using a murine
model system, Zagulski et al. (30) reported significant
protection from endotoxin shock by i.v. preadministration of LF. In the
current model, oral administration of LF is likely associated with
absorption of LF via the gastrointestinal tract and systemic
dissemination, as GF piglets have been demonstrated to be capable of
absorption of macromolecules for the first 3 days after birth
(16).
During the course of these studies, all animals were monitored
for additional clinical correlates of endotoxin shock, including temperature, food consumption, and activity level (Table 2). In BSA-fed
control animals, administration of LPS was followed immediately by the
rapid appearance of hypothermia in 100% of the animals and 74% of the
animals exhibiting hypothermia subsequently died. In contrast, only
38% of the LF-fed animals exhibited hypothermia and 13% subsequently
died (Fig. 1 and 2). The ability of LF to interfere with the induction
of hypothermia suggests that its locus of action is one or more of the
initial events leading to lethal shock. Endotoxin-induced shock is
thought to be at least in part a consequence of LPS activation of
monocytes/macrophages, followed by production of cytokines, including
TNF-
, IL-1, and IL-6 (23, 24). It has been demonstrated
that LF firmly binds to LPS (1, 7) and/or inactivates LPS
(26), which inhibits the endotoxin-induced TNF-
and IL-6
responses (14, 15). IL-6 is a major cause of hypothermia
(21), but TNF-
is not (21, 22). TNF-
is one
of the principal mediators of the lethal effect of endotoxin
(4).
A flow cytometric assay system developed to characterize LPS
interactions with porcine PBMs clearly demonstrated preferential binding of LPS to CD14-positive PBMs (Fig. 3), as is the case in humans
(29). Moreover, LF was able to inhibit LPS binding to
porcine PBMs in a dose-dependent fashion (Fig. 4), suggesting that the
ability to block in vivo endotoxin shock may be a consequence of
inhibition of LPS binding to monocytes. Although monocytes have been
reported to possess LF receptors (17), preliminary studies
using PBMs have shown that preincubation of PBMs with LF is ineffective
in blocking LPS binding if the cells are washed before addition of
LPS-FITC. When LF and LPS-FITC were mixed in vitro and added to PBMs
immediately or after preincubation for up to 60 min, the degrees of
inhibition of LPS binding to PBMs by LF were not significantly
different (8a). These observations and the fact that
pretreatment of PBMs with an anti-CD14 MAb blocked the binding of LPS
support the hypothesis that direct LF interaction with LPS may prevent
endotoxin from binding to the cell surface CD14 receptor and other
receptors of monocytes/macrophages and that this is followed by reduced
TNF-
production, as well as reduced IL-1 and IL-6 production,
resulting in a lower mortality rate in GF piglets challenged with
parenterally administered endotoxin.
 |
ACKNOWLEDGMENTS |
This work was supported in part by Ross Laboratories.
We acknowledge the assistance of Tony del Rosario, DVM; Larry Shannon;
and Remus Burchette in procuring animals for this study and Lisa
Roberts for technical assistance with in vitro studies.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Finch University of Health
Sciences/The Chicago Medical School, 3333 Green Bay Rd., North
Chicago, IL 60064. Phone: (847) 578-3230. Fax: (847) 578-3349. E-mail:
kimy{at}mis.finchcms.edu.
Present address: Department of Anatomy, College of Medicine, Seoul
National University, Seoul, Korea.
Editor: J. R. McGhee
 |
REFERENCES |
| 1.
|
Appelmelk, B. J.,
Y.-Q. An,
M. Geerts,
B. G. Thijs,
H. A. de Boer,
D. M. MacLaren,
J. de Graaff, and J. H. Nuijens.
1994.
Lactoferrin is a lipid A-binding protein.
Infect. Immun.
62:2628-2632[Abstract/Free Full Text].
|
| 2.
|
Arnold, R. R.,
M. Brewer, and J. J. Gauthier.
1980.
Bacterial activity of human lactoferrin: sensitivity of a variety of microorganisms.
Infect. Immun.
28:893-898[Abstract/Free Full Text].
|
| 3.
|
Arnold, R. R.,
J. E. Russell,
W. J. Champion, and J. J. Gauthier.
1981.
Bactericidal activity of human lactoferrin: influences of physical conditions and metabolic state of the target microorganisms.
Infect. Immun.
32:655-660[Abstract/Free Full Text].
|
| 4.
|
Beutler, B.,
I. W. Milsark, and A. C. Cerami.
1985.
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.
Science
229:869-871[Abstract/Free Full Text].
|
| 5.
|
Britigan, B. E.,
J. S. Serody, and M. S. Cohen.
1994.
The role of lactoferrin as an anti-inflammatory molecule.
Adv. Exp. Med. Biol.
357:143-156[Medline].
|
| 6.
|
Bullen, J. J.,
H. J. Rogers, and E. Griffiths.
1978.
Role of iron in bacterial infection.
Curr. Top. Microbiol. Immunol.
80:1-35[Medline].
|
| 7.
|
Elass-Rochard, E.,
A. Roseanu,
D. Logrand,
M. Trif,
V. Salmon,
C. Motas,
J. Montreuil, and G. Spik.
1995.
Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide.
Biochem. J.
312:839-845.
|
| 8.
|
Ellison, R. T., III, and T. J. Giehl.
1991.
Killing of gram-negative bacteria by lactoferrin and lysozymes.
J. Clin. Invest.
88:1080-1091.
|
| 8a.
| Farmer, J. L., and L. Roberts. Unpublished
data.
|
| 9.
|
Gutteberg, T. J.,
O. Rokke,
O. Anderson, and T. Joergensen.
1989.
Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: an early defence mechanism.
Scand. J. Infect. Dis.
21:708-715.
|
| 10.
|
Kim, Y. B., and D. W. Watson.
1965.
Modification of host responses to bacterial endotoxins. II. Passive transfer of immunity to bacterial endotoxin with fractions containing 19S antibodies.
J. Exp. Med.
121:751-759[Abstract].
|
| 11.
|
Kim, Y. B., and D. W. Watson.
1966.
Role of antibodies in reactions to gram-negative bacterial endotoxins.
Ann. N. Y. Acad. Sci.
133:727-745[Medline].
|
| 12.
|
Kim, Y. B., and D. W. Watson.
1967.
Biologically active endotoxin from salmonella mutants deficient in O- and R-polysaccharides and heptose.
J. Bacteriol.
94:1320-1326[Abstract/Free Full Text].
|
| 13.
|
Kim, Y. B.
1975.
Developmental immunity in the piglet, p. 549-557. In
D. Bergsma, R. A. Good, and J. Finnstad (ed.), Immunodeficiency in man and animals. Birth defects: original articles series, vol. XI (no. 1).
Sinauer Associates, Inc., Sunderland, Mass.
|
| 14.
|
Machnicki, M.,
M. Zimecki, and T. Zagulski.
1993.
Lactoferrin regulates the release of tumor necrosis factor alpha and interleukin 6 in vivo.
Int. J. Exp. Pathol.
74:433-439[Medline].
|
| 15.
|
Mattsby-Baltzer, I.,
A. Roseanu,
C. Motas,
J. Elverfors,
I. Engberg, and L. A. Hanson.
1996.
Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells.
Pediatr. Res.
40:157-262.
|
| 16.
|
Mehrazar, K.,
A. Gilman-Sachs, and Y. B. Kim.
1993.
Intestinal absorption of immunologically intact macromolecules in germfree colostrum-deprived piglets maintained on total parenteral nutrition.
J. Parenter. Enteral. Nutr.
17:8-15[Abstract].
|
| 17.
|
Miyazawa, K.,
C. Mantel,
L. Lu,
D. C. Morrison, and H. E. Broxymeyer.
1991.
Lactoferrin-lipopolysaccharide interactions: effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells.
J. Immunol.
146:723-729[Abstract].
|
| 18.
|
Naidu, S. S.,
U. Svensson,
A. R. Kishore, and A. S. Naidu.
1993.
Relationship between antibacterial activity and porin binding of lactoferrin in Escherichia coli and Salmonella typhimurium.
Antimicrob. Agents Chemother.
37:240-245[Abstract/Free Full Text].
|
| 19.
| Nitsche, D. August 1993. Use of lactoferrin for
treatment of toxic effect of endotoxins. U.S. patent 5,240,909, p.
1-16.
|
| 20.
|
Parrillo, J. E.
1993.
Pathogenetic mechanisms of septic shock.
N. Engl. J. Med.
328:1471-1477[Free Full Text].
|
| 21.
|
Schotanus, K.,
G. M. Holtkamp,
N. Van Rooijen,
F. J. M. Tilders, and F. Berkenbosch.
1995.
Circulating tumor necrosis factor- does not mediate endotoxin-induced hypothermia in rats.
Am. J. Physiol.
168:R989-R996.
|
| 22.
|
Tolchard, S.,
A. S. Hare,
D. J. Nutt, and G. Clarke.
1996.
TNF mimics the endocrine but not the thermoregulatory responses of bacterial lipopolysaccharide (LPS): correlation with FOS-expression in the brain.
Neuropharmacology
35:243-248[Medline].
|
| 23.
|
Tracey, K. J., and A. Cerami.
1987.
Cachectin/tumor necrosis factor and other cytokines in infectious disease.
Curr. Opin. Immunol.
1:454-461.
|
| 24.
|
Waage, A.,
P. Brandtzaeg,
A. Halstensen,
P. Kierulf, and T. Espevik.
1989.
The complex pattern of cytokines in serum from patients with meningococcal septic shock.
J. Exp. Med.
169:333-338[Abstract/Free Full Text].
|
| 25.
|
Wang, C.-S.,
W.-Y. Chan, and H. U. Kloer.
1984.
Comparative studies on the chemical and immunochemical properties of human milk, human pancreatic juice and bovine milk lactoferrin.
Comp. Biochem. Physiol.
78B:575-580.
|
| 26.
|
Wang, D.,
K. M. Pabst,
Y. Aida, and M. J. Pabst.
1995.
Lipopolysaccharide-inactivating activity of neutrophils is due to lactoferrin.
J. Leukocyte Biol.
57:865-874[Abstract].
|
| 27.
|
Watson, D. W., and Y. B. Kim.
1963.
Modification of host responses to bacterial endotoxins. I. Specificity of pyrogenic tolerance and the role of hypersensitivity in pyrogenicity, lethality, and skin reactivity.
J. Exp. Med.
118:425-446[Abstract].
|
| 28.
|
Weinberg, E. D.
1978.
Iron and infection.
Microbiol. Rev.
42:45-66[Free Full Text].
|
| 29.
|
Wright, S. D.,
R. A. Ramos,
P. S. Tobias,
R. J. Ulevitch, and J. C. Mathison.
1990.
CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.
Science
249:1431-1433[Abstract/Free Full Text].
|
| 30.
|
Zagulski, T.,
P. Lipinski,
A. Zagulska,
S. Broniek, and C. Morse.
1989.
Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo.
Br. J. Exp. Pathol.
70:697-704[Medline].
|
| 31.
|
Ziegler, E. J.,
C. J. Fisher, Jr.,
C. L. Sprung, et al.
1991.
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin.
N. Engl. J. Med.
324:429-436[Abstract].
|
Infect Immun, April 1998, p. 1421-1426, Vol. 66, No. 4
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lacasse, P., Lauzon, K., Diarra, M. S., Petitclerc, D.
(2008). Utilization of lactoferrin to fight antibiotic-resistant mammary gland pathogens. J ANIM SCI
86: 66-71
[Abstract]
[Full Text]
-
Krissansen, G. W.
(2007). Emerging Health Properties of Whey Proteins and Their Clinical Implications. J. Am. Coll. Nutr.
26: 713S-723S
[Abstract]
[Full Text]
-
Puddu, P., Carollo, M. G., Belardelli, F., Valenti, P., Gessani, S.
(2007). Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages. J. Leukoc. Biol.
82: 347-353
[Abstract]
[Full Text]
-
Wang, Y., Shan, T., Xu, Z., Liu, J., Feng, J.
(2006). Effect of lactoferrin on the growth performance, intestinal morphology, and expression of PR-39 and protegrin-1 genes in weaned piglets. J ANIM SCI
84: 2636-2641
[Abstract]
[Full Text]
-
Leon-Sicairos, N., Lopez-Soto, F., Reyes-Lopez, M., Godinez-Vargas, D., Ordaz-Pichardo, C., de la Garza, M.
(2006). Amoebicidal Activity of Milk, Apo-lactoferrin, sIgA and Lysozyme.. Clin Med Res
4: 106-113
[Abstract]
[Full Text]
-
Shalev, D. E., Rotem, S., Fish, A., Mor, A.
(2006). Consequences of N-Acylation on Structure and Membrane Binding Properties of Dermaseptin Derivative K4-S4-(1-13). J. Biol. Chem.
281: 9432-9438
[Abstract]
[Full Text]
-
Radzishevsky, I. S., Rotem, S., Zaknoon, F., Gaidukov, L., Dagan, A., Mor, A.
(2005). Effects of Acyl versus Aminoacyl Conjugation on the Properties of Antimicrobial Peptides. Antimicrob. Agents Chemother.
49: 2412-2420
[Abstract]
[Full Text]
-
Levy, O.
(2004). Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes. J. Leukoc. Biol.
76: 909-925
[Abstract]
[Full Text]
-
Ochoa, T. J., Noguera-Obenza, M., Ebel, F., Guzman, C. A., Gomez, H. F., Cleary, T. G.
(2003). Lactoferrin Impairs Type III Secretory System Function in Enteropathogenic Escherichia coli. Infect. Immun.
71: 5149-5155
[Abstract]
[Full Text]
-
Van Amersfoort, E. S., Van Berkel, T. J. C., Kuiper, J.
(2003). Receptors, Mediators, and Mechanisms Involved in Bacterial Sepsis and Septic Shock. Clin. Microbiol. Rev.
16: 379-414
[Abstract]
[Full Text]
-
Caccavo, D., Pellegrino, N. M., Altamura, M., Rigon, A., Amati, L., Amoroso, A., Jirillo, E.
(2002). Review: Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. Innate Immunity
8: 403-417
[Abstract]
-
Gomez, H. F., Ochoa, T. J., Herrera-Insua, I., Carlin, L. G., Cleary, T. G.
(2002). Lactoferrin Protects Rabbits from Shigella flexneri-Induced Inflammatory Enteritis. Infect. Immun.
70: 7050-7053
[Abstract]
[Full Text]
-
Elass, E., Masson, M., Mazurier, J., Legrand, D.
(2002). Lactoferrin Inhibits the Lipopolysaccharide-Induced Expression and Proteoglycan-Binding Ability of Interleukin-8 in Human Endothelial Cells. Infect. Immun.
70: 1860-1866
[Abstract]
[Full Text]
-
Navon-Venezia, S., Feder, R., Gaidukov, L., Carmeli, Y., Mor, A.
(2002). Antibacterial Properties of Dermaseptin S4 Derivatives with In Vivo Activity. Antimicrob. Agents Chemother.
46: 689-694
[Abstract]
[Full Text]
-
Yamaguchi, M., Matsuura, M., Kobayashi, K., Sasaki, H., Yajima, T., Kuwata, T.
(2001). Lactoferrin Protects against Development of Hepatitis Caused by Sensitization of Kupffer Cells by Lipopolysaccharide. CVI
8: 1234-1239
[Abstract]
[Full Text]
-
Edde, L., Hipolito, R. B., Hwang, F. F. Y., Headon, D. R., Shalwitz, R. A., Sherman, M. P.
(2001). Lactoferrin protects neonatal rats from gut-related systemic infection. Am. J. Physiol. Gastrointest. Liver Physiol.
281: G1140-G1150
[Abstract]
[Full Text]
-
Baveye, S., Elass, E., Fernig, D. G., Blanquart, C., Mazurier, J., Legrand, D.
(2000). Human Lactoferrin Interacts with Soluble CD14 and Inhibits Expression of Endothelial Adhesion Molecules, E-Selectin and ICAM-1, Induced by the CD14-Lipopolysaccharide Complex. Infect. Immun.
68: 6519-6525
[Abstract]
[Full Text]
-
Levy, O.
(2000). Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood
96: 2664-2672
[Abstract]
[Full Text]
-
Wakabayashi, H., Uchida, K., Yamauchi, K., Teraguchi, S., Hayasawa, H., Yamaguchi, H.
(2000). Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J Antimicrob Chemother
46: 595-602
[Abstract]
[Full Text]
-
Caccavo, D., Afeltra, A., Pece, S., Giuliani, G., Freudenberg, M., Galanos, C., Jirillo, E.
(1999). Lactoferrin-Lipid A-Lipopolysaccharide Interaction: Inhibition by Anti-Human Lactoferrin Monoclonal Antibody AGM 10.14. Infect. Immun.
67: 4668-4672
[Abstract]
[Full Text]